• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017 - Product Image

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017

  • Published: April 2013
  • Region: Global
  • 360 Pages
  • Markets and Markets

FEATURED COMPANIES

  • Bracco Imaging SPA
  • Cardinal Health, Inc
  • Covidien, Plc
  • Eczacibasi-Monrol
  • Iba Group
  • Nordion, Inc
  • MORE

'Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017'

The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lion’s share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope. Furthermore, the PET market will witness a double digit growth during the forecast period.

The therapeutic segment contributes only 10% to the global radiopharmaceuticals market and I-131 has been considered as the gold standard for various oncology treatments in a combined therapy. Global nuclear medicines market is majorly driven by the increasing adoption of PET and SPECT scanners, and rising awareness for radiopharmaceuticals, whereas short half life of isotopes and stringent regulations are the factors that are hindering the growth of radiopharmaceuticals worldwide.

Besides highly preferred isotopes such as Tc-99m and F-18, significant growth is witnessed for READ MORE >

1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary

3 Market Overview
3.1 Definition Of Radiopharmaceuticals
3.2 Evolution
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints
3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals Restricts Its Usage
3.4.2.2 High Capital To Limit The Buying Of Scanners
3.4.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
3.4.2.4 Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities
3.4.3.1 Potential Radioisotopes In The Pipeline
3.4.3.2 High Demand In Emerging Countries
3.4.3.3 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment
3.4.3.4 Alternative Diagnostic Radiopharmaceutical Solutions
3.4.3.5 Cyclotron Based Production
3.4.3.6 Neurological Applications
3.4.4 Threat
3.4.4.1 Shutdown Of Nuclear Reactors To Impact Production Of Radioisotopes
3.5 Winning Imperatives
3.5.1 Investments On New Radioisotopes And Novel Applications
3.5.2 Shift Towards Leu-Based Mo-99 Production
3.6 Burning Issues
3.6.1 High Cost Of Pet Cameras
3.6.2 Shortage In Supply Of Technetium-99m
3.7 Market Share Analysis
3.7.1 Radiopharmaceuticals Market
3.7.2 Enriched Stable Isotopes Market
3.8 Value Chain Analysis
3.8.1 Spect (Molybdenum-99/Technetium-99m)
3.8.1.1 Pricing Structure In Different Phases Of The Value Chain
3.8.1.2 Cost Modeling – Leu Based Tc-99m Production
3.8.2 Pet (Fluorine-18)
3.8.3 Stable Isotope (DEUTERIUM)
3.9 Pipeline Analysis
3.9.1 Diagnostic Radioisotopes
3.9.2 Therapeutic Radioisotopes
3.10 Demand & Supply Analysis
3.10.1 Demand For Mo-99/Tc-99m
3.10.1.1 Availability Of Spect Cameras To Stabilize Demand
3.10.1.2 Stringent Regulatory And Reimbursement Procedures For Alternative Isotopes Prevents Shift From Tc-99
3.10.1.3 Emerging Markets Will Enhance Usage Of Tc-99m
3.10.1.4 Potential Growth Of Tc-99m Based Diagnostic Imaging
3.10.1.5 Shift From Spect To Pet
3.10.2 Current Status Of Mo-99 Supply
3.11 Strategic Benchmarking
3.11.1 Processors’ Shift From Heu To Leu Based Mo-99
3.11.1.1 Contract Extension By Nordion With Aecl & Supply Agreement With Riar
3.11.1.2 Agreement Of Covidien & Iae Polatom With Maria Reactor
3.11.1.3 Agreement Of Ntp Radioisotopes With Lantheus Medical Imaging
3.11.2 Sustainable Supply Chain By Generators
3.11.2.1 Contract Extension Of Lantheus Medical Imaging Inc., With Ntp Radioisotopes (PTY) Ltd.
3.11.2.2 Extension Of Contract & Acquisition By Iba Group
3.11.2.3 Acquisition Of Cns Therapeutics, Inc., By Covidien, Plc.
3.11.2.4 Collaboration Of Ntp Radioisotopes Pty Ltd. With Ansto
3.11.2.5 Expansion And Agreement Of Fujifilm Holdings Corporation
3.12 Regulatory Affairs
3.12.1 Guidelines In The U.S.
3.12.2 Guidelines In Europe
3.12.3 Reimbursement
3.12.4 Safety Of Personnel
3.12.5 Waste Disposal
3.12.6 Equipment & Facility
3.12.7 Transportation Guidelines

4 Global Radiopharmaceuticals Market, By Value
4.1 Introduction
4.2 Diagnostic Market
4.2.1 Opportunity Matrix
4.2.2 Spect Radiopharmaceuticals
4.2.2.1 Technetium-99m (TC-99m)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Lack Of Availability Of Technetium
4.2.2.2 Thallium-201 (TL-201)
4.2.2.2.1 Tl-201 Is A Potential Substitute For TC-99m
4.2.2.3 Gallium-67 (GA-67)
4.2.2.3.1 Fluorine-18 Might Seize Ga-67 Market Share In The Near Future
4.2.2.4 Iodine (I-123)
4.2.2.5 Others
4.2.3 Pet Radiopharmaceuticals
4.2.3.1 Fluorine-18
4.2.3.1.1 Fdg
4.2.3.1.2 Florbetapir
4.2.3.1.3 Factors Affecting Fluorine-18 Market
4.2.3.1.3.1 Increasing Availability Of Pet Machines
4.2.3.1.3.2 Rise In Pet Procedures Increases Demand For Fdg
4.2.3.1.3.3 High Generation Costs Of Fdg
4.2.3.1.3.4 Need For Speedy & Efficient Transportation
4.2.3.2 Rubidium-82 (RB-82)
4.2.3.2.1 Bracco Re-Launched Cardiogen-82 In Feb-12
4.2.3.3 Others
4.2.3.3.1 Ga-68 Deemed As A Potential Pet Radioisotope
4.3 Therapeutic Market
4.3.1 Opportunity Matrix
4.3.2 Beta Emitters
4.3.2.1 Iodine-131 (I-131)
4.3.2.2 Yttrium-90 (Y-90)
4.3.2.2.1 Y-90 Market Influenced By Popularity Of Nordion’s Therasphere
4.3.2.3 Samarium-153 (SM-153)
4.3.2.4 Rhenium-186 (RE-186)
4.3.2.5 Lutetium-177 (LU-177)
4.3.2.5.1 LU-177 Is A Potential Treatment Option For Neuroendocrine Cancer
4.3.2.6 Others
4.3.2.6.1 Re-188 And P-33 Are Notable Promising Isotope
4.3.3 Alpha Emitters
4.3.3.1 Radium-223 (RA-223) & Alpharadin
4.3.3.1.1 Successful Completion Of Phase Iii Trials In Men With Bone Metastases From Crpc
4.3.3.1.2 First In-Class Alpha Pharmaceutical
4.3.3.1.3 Alpharadin Is Advantageous Over Taxotere, Beta-Therapy And Brachytherapy
4.3.3.1.4 Success Of Alpharadin
4.3.3.1.5 Porter’s Five Forces Analysis
4.3.3.1.6 Alpharadin Market Potential Post Launch
4.3.3.1.7 Swot Analysis
4.3.3.2 Actinium-225 (AC-225)
4.3.3.3 Lead-212 (PB-212)/Bismuth-212 (BI-212)
4.3.3.4 Astatine-211 (AT-211)
4.3.3.5 Radium-224 (RA-224)
4.3.3.6 Thorium-227 (TH-227)
4.3.4 Brachytherapy
4.3.4.1 U.S. To Show Slow Growth Due To Reimbursement Issues
4.3.4.2 Cesium-131
4.3.4.3 Iodine-125
4.3.4.4 Palladium-103
4.3.4.5 Iridium-192
4.3.4.6 Others

5 Global Radiopharmaceuticals Market, By Procedural Volume
5.1 Introduction
5.1.1 Hospital Based & Local Reactors Generated Isotopes To Boost The Procedural Market
5.2 Diagnostic Market
5.2.1 Spect Radiopharmaceuticals
5.2.2 Pet Radiopharmaceuticals
5.3 Therapeutic Market
5.3.1 Beta Emitters
5.3.2 Brachytherapy

6 Radiopharmaceuticals Market, By Application/Indication
6.1 Introduction
6.2 Diagnostic Market
6.2.1 Spect
6.2.1.1 Cardiology
6.2.1.2 Lymphoma
6.2.1.3 Thyroid
6.2.1.4 Neurology
6.2.1.4.1 Alzheimer’s, Dementia, And Parkinson’s Disease Drives Growth Of The Neurology Spect Market
6.2.1.5 Others
6.2.2 Pet Application
6.2.2.1 Oncology
6.2.2.1.1 Fdg F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan
6.2.2.2 Cardiology
6.2.2.3 Neurology
6.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 Dopa) Are Potential Substitutes Of Fdg F-18
6.2.2.4 Others
6.3 Therapeutic Application
6.3.1 Thyroid
6.3.2 Bone Metastasis
6.3.3 Lymphoma
6.3.3.1 Novel Clinical Studies Goading Lymphoma Therapy Market
6.3.4 Endocrine Tumors
6.3.5 Others

7 Enriched Stable Isotopes Market
7.1 Introduction
7.2 Market Overview
7.2.1 Asia Accounts For The Largest Market Share
7.3 Market Dynamics
7.3.1 Drivers
7.3.1.1 Stable Isotopes Are Natural In Origin & Hence Safe
7.3.1.2 Proteomics & System Biology, Major Factors To Boost The Growth Of Stables
7.3.1.3 Medical Applications Propel Stable Isotopes Market Growth
7.3.2 Restraints
7.3.2.1 Harmful Effects Of Stable Isotopes Affect Market Growth
7.3.2.2 High Cost Of Stables Isotope
7.4 Enriched Stables Market, By Isotopes
7.4.1 Deuterium & O-18 Are Promising Isotopes
7.4.2 Carbon-13
7.4.3 Deuterium
7.4.4 Oxygen-18
7.4.5 Nitrogen-15
7.4.6 Other Stable Isotopes
7.5 Enriched Stables Market, By Applications
7.5.1 Diagnostic & Therapeutic
7.5.2 Research
7.5.3 Pharmaceuticals
7.5.4 Industrial Sector

8 Geographic Analysis
8.1 Introduction
8.2 Diagnostic Market
8.2.1 North America
8.2.1.1 Increasing Adoption Of Alternative Production Technologies To Make Up For The Shortage Of Mo-99
8.2.2 Europe
8.2.2.1 Spect And Pet Contributes Almost Equal In Europe
8.2.2.2 Stringent Regulations Hindering Market Growth
8.2.3 Asia
8.2.3.1 Asia Promises The Highest Cagr In The Forecast Period
8.2.4 Rest Of The World (Row)
8.3 Therapy Market
8.3.1 North America
8.3.1.1 Nuclear Medicine Research Drives The Beta Emitters Market
8.3.2 Europe
8.3.3 Asia
8.3.4 Rest Of The World (Row)
8.4 Enriched Stable Isotopes Market
8.4.1 Asia
8.4.2 North America
8.4.3 Europe
8.4.4 Rest Of The World (Row)

9 Competitive Landscape
9.1 Introduction
9.2 Mergers & Acquisitions
9.3 Agreements, Partnerships, Collaborations & Joint Ventures
9.4 Products Launch
9.5 Expansions
9.6 Other Developments
9.7 Approvals

10 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*
10.1 Companies
10.1.1 Bracco Imaging S.P.A.
10.1.2 Cambridge Isotope Laboratories, Inc.
10.1.3 Cardinal Health, Inc.
10.1.4 Covidien, Plc
10.1.5 Eczacibasi-Monrol
10.1.6 Fujifilm Holdings Corporation
10.1.7 Ge Healthcare (Subsidiary Of General Electric Company)
10.1.8 Iba Group
10.1.9 Isotec, Inc. (Sigma-Aldrich)
10.1.10 Lantheus Medical Imaging, Inc.
10.1.11 Nordion, Inc.
10.1.12 Ntp Radioisotopes (PTY), Ltd.
10.1.13 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
10.1.14 Taiyo Nippon Sanso Corporation
10.1.15 Urenco Limited
10.1.16 Rotem Industries, Ltd., Inc.
10.2 Institutes
10.2.1 Australian Nuclear Association And Technology Organization (Ansto)
10.2.2 Board Of Radiation And Isotope Technology (Brit)
10.2.3 Institute Of Atomic Energy Polatom Radioisotope Centre
10.2.4 Institute Of Isotopes Co., Ltd.
10.2.5 Institute Of Radioelement (IRE)

*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.

List Of Tables (153 Tables)

Table 1 Radiopharmaceutical Diagnostic Market, By Technology, 2010 – 2017 ($Million)
Table 2 Cost Increase Of Tc-99m: Phases Of Supply Chain (%)
Table 3 Cost Range: New & Modified Rig ($Million)
Table 4 Cost Range: New & Modified Containers ($Million)
Table 5 Cost Increase For Leu-Based Conversion (%)
Table 6 Cost Impact: Phases Of Supply Chain ($/6-Day Curie)
Table 7 Details Of Radiopharmaceuticals For Upcoming Diagnostic Applications, 2010 – 2017
Table 8 Details Of Radiopharmaceuticals For Upcoming Therapeutic Applications, 2010 – 2017
Table 9 Mo-99: Weekly Demand (2011)
Table 10 Mo-99: Production Per Week (2010)
Table 11 Tc-99m: Processing Capacity (2011)
Table 12 Mo-99: Potential Reactors
Table 13 Global Radiopharmaceutical Diagnostic Market, By Technology, 2010 – 2017 ($Million)
Table 14 Global Spect Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 15 Spect Radiopharmaceutical Market, By Geography, 2010 – 2017 ($Million)
Table 16 Indications Diagnosed By Tc-99m
Table 17 Tc-99m Market, By Geography, 2010 – 2017 ($Million)
Table 18 Tl-201 Market, By Geography, 2010 – 2017 ($Million)
Table 19 Ga-67 Market, By Geography, 2010 – 2017 ($Million)
Table 20 I-123 Market, By Geography, 2010 – 2017 ($Million)
Table 21 Other Radiopharmaceuticals Market, By Geography, 2010 – 2017 ($Million)
Table 22 Pet Radiopharmaceuticals Market, By Geography, 2010 – 2017 ($Million)
Table 23 Global Pet Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million)
Table 24 F-18 Market, By Geography, 2010 – 2017 ($Million)
Table 25 Rb-82 Market, By Geography, 2010 – 2017 ($Million)
Table 26 Other Pet Radiopharmaceuticals Market, By Geography, 2010 – 2017 ($Million)
Table 27 Global Beta Emitter Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million)
Table 28 Beta Emitter Radiopharmaceuticals Market, By Geography, 2010 – 2017 ($Million)
Table 29 I-131 Market, By Geography, 2010 – 2017 ($Million)
Table 30 Y-90 Market, By Geography, 2010 – 2017 ($Million)
Table 31 Sm-153 Market, By Geography, 2010 – 2017 ($Million)
Table 32 Re-186 Market, By Geography, 2010 – 2017 ($Million)
Table 33 Lu-177 Market, By Geography, 2010 – 2017 ($Million)
Table 34 Other Beta-Emitter Radiopharmaceuticals Market, By Geography, 2010 – 2017 ($Million)
Table 35 Alpha Emitters Vs Beta Emitters
Table 36 Hrpca Bone Metastasis Therapy Market & Alpharadin Addressable Market, 2015 ($Million)
Table 37 Radioisotope Characteristics & Dose Delivery Over Time
Table 38 Global Brachytherapy Market, By Isotope, 2010 – 2017 ($Million)
Table 39 Brachytherapy Market, By Geography, 2010 – 2017 ($Million)
Table 40 Cs-131 Market, By Geography, 2010 – 2017 ($Million)
Table 41 I-125 Market, By Geography, 2010 – 2017 ($Million)
Table 42 Pd-103 Market, By Geography, 2010 – 2017 ($Million)
Table 43 Ir-192 Market, By Geography, 2010 – 2017 ($Million)
Table 44 Other Brachytherapy Isotopes Market, By Geography, 2010 – 2017 ($Million)
Table 45 Radiopharmaceutical Procedures Market, By Geography, 2010 – 2017 (Million)
Table 46 Global Diagnostic Radiopharmaceutical Procedures Market, By Technology, 2010 – 2017 (Million)
Table 47 Global Spect Radiopharmaceutical Procedures Market, By Isotope, 2010 – 2017 (Million)
Table 48 Spect Radiopharmaceutical Procedures Market, By Geography, 2010 – 2017 (Million)
Table 49 Global Pet Radiopharmaceutical Procedures Market, By Isotope, 2010 – 2017 (Million)
Table 50 Pet Radiopharmaceutical Procedures Market, By Geography, 2010 – 2017 (Million)
Table 51 Global Therapeutic Radiopharmaceutical Procedures Market, By Type, 2010 – 2017 (Million)
Table 52 Global Beta Emitter Procedures Market, By Isotope, 2010 – 2017 (Million)
Table 53 Beta Emitters Radiopharmaceutical Procedures Market, By Geography, 2010 – 2017 (Million)
Table 54 Global Brachytherapy Procedures Market, By Isotope, 2010 – 2017 (Million)
Table 55 Brachytherapy Radiopharmaceuticals Market, By Geography, 2010 – 2017 (Million)
Table 56 Spect Application Market, 2010 – 2017 ($Million)
Table 57 Cardiology Spect Market, By Geography, 2010 – 2017 ($Million)
Table 58 Lymphoma Spect Market, By Geography, 2010 – 2017 ($Million)
Table 59 Thyroid Spect Market, By Geography, 2010 – 2017 ($Million)
Table 60 Neurology Spect Market, By Geography, 2010 – 2017 ($Million)
Table 61 Other Spect Applications Market, By Geography, 2010 – 2017 ($Million)
Table 62 Global Pet Application Market, 2010 – 2017 ($Million)
Table 63 Oncology Pet Market, By Geography, 2010 – 2017 ($Million)
Table 64 Cardiology Pet Market, By Geography, 2010 – 2017 ($Million)
Table 65 Neurology Pet Market, By Geography, 2010 – 2017 ($Million)
Table 66 Other Pet Applications Market, By Geography, 2010 – 2017 ($Million)
Table 67 Global Radiopharmaceutical Market For Therapeutic Applications,2010 – 2017 ($Million)
Table 68 Radiopharmaceutical Market For Therapeutic Applications, By Geography,2010 – 2017 ($Million)
Table 69 Therapeutic Radiopharmaceutical Market For Thyroid Application, By Geography,2010 – 2017 ($Million)
Table 70 Therapeutic Radiopharmaceutical Market For Bone Metastasis Application, By Geography, 2010 – 2017 ($Million)
Table 71 Therapeutic Radiopharmaceutical Market For Lymphoma Application, By Geography, 2010 – 2017 ($Million)
Table 72 Therapeutic Radiopharmaceutical Market For Endocrine Application, By Geography, 2010 – 2017 ($Million)
Table 73 Therapeutic Radiopharmaceutical Market For Other Applications, By Geography, 2010 – 2017 ($Million)
Table 74 Global Stable Isotope Market, 2010 – 2017 ($Million)
Table 75 Stable Isotope Market, By Geography, 2010 – 2017 ($Million)
Table 76 Carbon Stable Isotope Market, By Geography, 2010 – 2017 ($Million)
Table 77 Deuterium Stable Isotope Market, By Geography, 2010 – 2017 ($Million)
Table 78 Oxygen Stable Isotope Market, By Geography, 2010 – 2017 ($Million)
Table 79 Nitrogen Stable Isotope Market, By Geography, 2010 – 2017 ($Million)
Table 80 Other Stable Isotope Market, By Geography, 2010 – 2017 ($Million)
Table 81 Global Enriched Stable Isotope Market, By Application, 2010 – 2017 ($Million)
Table 82 Stable Isotopes Market For Medical Applications, By Geography, 2010 – 2017 ($Million)
Table 83 Stable Isotopes Market For Research Applications, By Geography, 2010 – 2017 ($Million)
Table 84 Stable Isotopes Market For Pharmaceutical Applications, By Geography, 2010 – 2017 ($Million)
Table 85 Stable Isotopes Market For Industrial Applications, By Geography, 2010 – 2017 ($Million)
Table 86 Diagnostic Radiopharmaceuticals Market, By Geography, 2010 – 2017 ($Million)
Table 87 Spect Radiopharmaceuticals Market, By Geography, 2010 – 2017 ($Million)
Table 88 Pet Radiopharmaceuticals Market, By Geography, 2010 – 2017 ($Million)
Table 89 North America: Radiopharmaceutical Diagnostic Market, By Technology, 2010 – 2017 ($Million)
Table 90 North America: Spect Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 91 North America: Pet Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 92 Europe: Radiopharmaceutical Diagnostic Market, By Technology, 2010 – 2017 ($Million)
Table 93 Europe: Spect Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 94 Europe: Pet Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 95 Asia: Radiopharmaceutical Diagnostic Market, By Technology, 2010 – 2017 ($Million)
Table 96 Asia: Spect Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 97 Asia: Pet Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 98 Row: Radiopharmaceutical Diagnostic Market, By Technology, 2010 – 2017 ($Million)
Table 99 Row: Spect Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 100 Row: Pet Radiopharmaceutical Market, By Isotope, 2010 – 2017 ($Million)
Table 101 Beta Emitter Market, By Geography, 2010 – 2017 ($Million)
Table 102 Brachytherapy Market, By Geography, 2010 – 2017 ($Million)
Table 103 North America: Radiopharmaceutical Market, By Therapy, 2010 – 2017 ($Million)
Table 104 North America: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million)
Table 105 North America: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 106 Europe: Radiopharmaceutical Market, By Therapy, 2010 – 2017 ($Million)
Table 107 Europe: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million)
Table 108 Europe: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 109 Asia: Radiopharmaceutical Market, By Therapy, 2010 – 2017 ($Million)
Table 110 Asia: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million)
Table 111 Asia: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 112 Row: Radiopharmaceutical Market, By Therapy, 2010 – 2017 ($Million)
Table 113 Row: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million)
Table 114 Row: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 115 Enriched Stable Isotope Market, By Geography, 2010 – 2017 ($Million)
Table 116 Asia: Stable Isotope Market, 2010 – 2017 ($Million)
Table 117 Asia: Enriched Stable Isotope Market, By Application, 2010 – 2017 ($Million)
Table 118 North America: Enriched Stable Isotope Market, 2010 – 2017 ($Million)
Table 119 North America: Stable Isotope Market, By Application, 2010 – 2017 ($Million)
Table 120 Europe: Enriched Stable Isotope Market, 2010 – 2017 ($Million)
Table 121 Europe: Enriched Stable Isotope Market, By Application, 2010 – 2017 ($Million)
Table 122 Row: Enriched Stable Isotope Market, 2010 – 2017 ($Million)
Table 123 Row: Enriched Stable Isotope Market, By Application, 2010 – 2017 ($Million)
Table 124 Mergers & Acquisitions, 2010 – 2012
Table 125 Agreements, Partnerships, Collaborations & Joint Ventures, 2010 – 2013
Table 126 Products Launch, 2010 – 2013
Table 127 Expansions, 2010 – 2012
Table 128 Other Developments, 2010 – 2012
Table 129 Approvals, 2010 – 2011
Table 130 Cambridge Isotope Laboratories Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 131 Cambridge Isotope Laboratories Inc.: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 132 Cardinal Health, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 133 Cardinal Health, Inc.: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 134 Covidien, Plc: Total Revenue And R&D Expenditure, 2010 – 2012 ($Million)
Table 135 Covidien, Plc: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 136 Covidien, Plc: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 137 Fujifilm Holdings Corp: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 138 Fujifilm Holdings Corp: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 139 General Electric Company: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion)
Table 140 General Electric Company: Total Revenue, By Segment, 2009 – 2011 ($Billion)
Table 141 General Electric Company: Total Revenue, By Geography, 2009 – 2011 ($Billion)
Table 142 Iba Group: Market Revenue, By Segment, 2009 – 2011 ($Million)
Table 143 Iba Group: Total Revenue, By Geography, 2009 – 2011 ($Million)
Table 144 Isotec Inc.: Total Revenue, By Segment, 2009 – 2011 ($Million)
Table 145 Isotec Inc.: Total Revenue, By Geography, 2009 – 2011 ($Million)
Table 146 Lantheus: Total Revenue, By Segment, 2009 – 2011 ($Million)
Table 147 Lantheus: Total Revenue, By Geography, 2009 – 2011 ($Million)
Table 148 Nordion, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 149 Nordion, Inc.: Total Revenue, By Geography, 2009 – 2011 ($Million)
Table 150 Siemens Ag: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)
Table 151 Siemens Ag: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 152 Siemens Ag: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 153 Taiyo Nippon Sanso, Corp.: Total Revenue, By Geography, 2010 – 2012 ($Million)

List Of Figures (45 Figures)

Figure 1 Global Radiopharmaceutical Market, By Segment, 2010 – 2017
Figure 2 Radiopharmaceuticals Market, By Geography, 2012 ($Million)
Figure 3 Global Stable Isotopes Market, 2012 – 2017 ($Million)
Figure 4 Evolution Of Radiopharmaceuticals
Figure 5 Radiopharmaceuticals Market Segmentation
Figure 6 Enriched Stable Isotopes Market Segmentation
Figure 7 Market Dynamics
Figure 8 Radiopharmaceuticals: Market Share Analysis, By Key Players, 2012
Figure 9 Enriched Stable Isotope: Market Share Analysis, By Key Players, 2012
Figure 10 Mo-99/Tc-99m: Supply Chain
Figure 11 Tc-99m: Supply Chain Participants
Figure 12 Tc-99m: Value Chain Analysis
Figure 13 Tc-99m: Pricing Factors
Figure 14 Fluorine-18: Supply Chain
Figure 15 Deuterium: Supply Chain
Figure 16 Major Sponsors, Clinical Studies, 2010 – 2017
Figure 17 Clinical Trials For Diagnostic & Therapeutic Applications Of Radioisotopes, By Phase, 2010 – 2017
Figure 18 Clinical Trials (Phase Iii & Iv) For Diagnostic Radioisotopes, 2010 – 2017
Figure 19 Upcoming Radiopharmaceutical Applications (Diagnosis), 2010 – 2017
Figure 20 Clinical Trials (Phase Iii & Iv) For Therapeutic Radioisotopes, 2010 – 2017
Figure 21 Upcoming Radiopharmaceutical Applications (Therapy), 2010 – 2017
Figure 22 Mo-99 Demand (Six Days Curie) Per Week, 2012 Vs 2030
Figure 23 Mo-99: Supply Vs Demand Analysis, 2010 – 2020
Figure 24 Shift Towards Leu From Heu
Figure 25 Sustainable Supply Chain & Logistics
Figure 26 Opportunity Matrix: Global Diagnostic Radiopharmaceuticals Market (2012)
Figure 27 Spect Radioisotope Market Share (2012)
Figure 28 Pet Radiopharmaceuticals Market Share (2012)
Figure 29 Opportunity Matrix: Global Therapeutic Radiopharmaceuticals Market (2012)
Figure 30 Ra-223 Decay Chain
Figure 31 Porter’s Five Forces Analysis For Alpharadin
Figure 32 Swot Analysis Of Alpharadin
Figure 33 Global Radiopharmaceutical Procedures Market, 2012
Figure 34 Diagnostic Radiopharmaceuticals Market, By Indication (2012)
Figure 35 Key Growth Strategies, 2010 – 2013
Figure 36 Cambridge Isotope Laboratories Inc.: Total Revenue And R&D Expenses, 2010 – 2012 ($Billion)
Figure 37 Cardinal Health, Inc.: Total Revenue, 2010 – 2012 ($Billion)
Figure 38 Covidien, Plc: Radiopharmaceuticals Revenue, 2010 – 2012 ($Million)
Figure 39 Fujifilm Holdings Corp: Total Revenue And R&D Expenditure, 2010 – 2012 ($Billion)
Figure 40 IBA Group: Total Market Revenue, 2009 – 2011 ($Million)
Figure 41 Isotec Inc.: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion)
Figure 42 Lantheus: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)
Figure 43 Nordion, Inc.: Total Market Revenue, 2010 – 2012 ($Million)
Figure 44 Taiyo Nippon Sanso, Corp.: Total Revenue And R&D Expenditure, 2010 – 2012 ($Billion)
Figure 45 Urenco Limited: Total Market Revenue, 2009 – 2011 ($Billion)

Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used for disease diagnosis and treatment. They provide increased understanding of diseases as they not only give anatomical but also functional information about the organ. Radiopharmaceuticals are also used in the nuclear imaging field as tracers. They are mostly used for diagnosis with the use of gamma cameras for imaging techniques such as in SPECT and PET. Radioisotopes are used in medical applications with more than 90% share. Medical application is driven by the increasing patient population and new and effective radioisotopes. The most commonly used isotopes for diagnosis are Tc-99m and Tl-201 for SPECT and F-18 for PET.

The radiopharmaceuticals market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 85% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201 (Tl-201), gallium-;67 (Ga-67) and iodine-123 (I-123). SPECT is majorly used in the diagnosis of cardiac diseases; it is poised to grow at a stable CAGR from 2012 to 2017. The PET radioisotopes market is dominated by fluorine-18 (F-18), followed by rubidium-82 (Rb-82) and poised to grow at a CAGR of more than 10% in the near future.

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters is not conclusive, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131(I-153), which is poised to grow at a decent CAGR of about 5.0% from 2012 to 2017. The market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin-s lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192). North America is the major market for brachytherapy in terms of market share, followed by Europe. However, it is showing slow growth due to reimbursement issues.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects.The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

North America is the dominant market for diagnostic radioisotopes with about half the share. The U.S. is the largest consumer market for radiopharmaceuticals, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc., Covidien, Plc, GE Healthcare, IBA Group, Lantheus Medical Imaging, Inc., Nordion, Inc., and Siemens Healthcare (PETNET).

The stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). It has major applications in research, pharmaceuticals, diagnostic and therapy, and the industrial sector. The medical applications market accounted for the maximum share of the stable isotopes market. The global stable isotopes market is estimated to reach close to $250 million by 2017 at a CAGR of more than 10%. The market was led by two players - Cambridge Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they jointly contributed more than 90% to the global revenue.

- Bracco Imaging SPA
- Cambridge Isotope Laboratories, Inc
- Cardinal Health, Inc
- Covidien, Plc
- Eczacibasi-Monrol
- Fujifilm Holdings Corporation
- Ge Healthcare (Subsidiary Of General Electric Company)
- Iba Group
- Isotec, Inc (Sigma-Aldrich)
- Lantheus Medical Imaging, Inc
- Nordion, Inc
- Ntp Radioisotopes (PTY), Ltd
- Petnet Solutions, Inc (A Subsidiary Of Siemens Medical Solutions Usa, Inc)
- Rotem Industries, Ltd, Inc
- Taiyo Nippon Sanso Corporation
- Urenco Limited

Institutes Mentioned in the Report

- Australian Nuclear Association And Technology Organization (Ansto)
- Board Of Radiation And Isotope Technology (Brit)
- Institute Of Atomic Energy Polatom Radioisotope Centre
- Institute Of Isotopes Co, Ltd
- Institute Of Radioelement (IRE)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos